Tanvex BioPharma Inc. completed its acquisition of Bora Biotech, a subsidiary of Bora Pharmaceutical Co., in a move to strengthen its position in the global biologics contract manufacturing market.
The merged entity will operate under the Bora Biologics brand, leveraging Tanvex’s FDA-approved manufacturing facility in San Diego and Bora’s early-stage development capabilities in Taiwan. Bora Pharmaceutical Chairman Sean Shih will lead the combined company as the new chairman of Tanvex.
The deal combines Tanvex’s commercial-scale biologics production expertise with Bora Biotech’s track record in early-stage contract development. Over the past two years, Bora Biotech has completed more than 35 CDMO projects with a 100% on-time delivery rate.
Stephen Lam will continue as CEO, overseeing operations that span from early-stage development in Taiwan to commercial manufacturing at the 2,000-liter San Diego facility. The company’s biosimilar products will maintain the Tanvex brand to ensure continuity in development and production.
The merger positions the company to compete in the growing biologics CDMO market, offering clients an integrated supply chain that includes U.S.-based fill-finish capabilities.
